Drug intelligence / Profile preview

placebo gel-Veloce BioPharma LLC-verruca vulgaris

Development stage: Unknown
Lead developer: Veloce BioPharma
Administration: Topical

Overview

The placebo gel developed by Veloce BioPharma LLC is an inert topical formulation used as a control in clinical trials, specifically the Phase 2 study (NCT04253912) for verruca vulgaris (common warts). It is designed to be physically identical to VBP-245, a 2% povidone-iodine gel, but lacks the active antiseptic ingredient. The gel is applied topically to warts on the trunk or extremities. Veloce BioPharma uses this comparator to evaluate the efficacy and safety of their povidone-iodine platform in treating viral skin infections, including common warts and molluscum contagiosum.

Other names: Placebo Gel (no Povidone-Iodine)

Beyond the preview

Go deeper on placebo gel-Veloce BioPharma LLC-verruca vulgaris.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on placebo gel-Veloce BioPharma LLC-verruca vulgaris.

Explore the full profile